Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jean Marc Duclos is active.

Publication


Featured researches published by Jean Marc Duclos.


The Journal of Urology | 2003

Laparoscopic Management of Primary Hyperaldosteronism: Clinical Experience with 212 Cases

Paul Meria; Béatrice Fiquet Kempf; Jean François Hermieu; Pierre François Plouin; Jean Marc Duclos

PURPOSE Laparoscopy is now widely used to remove benign adrenal tumors. We assessed the value of transperitoneal partial or total adrenalectomy for primary hyperaldosteronism. MATERIALS AND METHODS From September 1994 to October 2001, 212 consecutive patients with a mean age of 48 years who presented with primary hyperaldosteronism and related arterial hypertension underwent transperitoneal laparoscopic adrenalectomy (193) or tumor enucleation (20) performed by a single surgeon, including 1 who underwent bilateral adrenalectomy. In all cases preoperatively high plasma and urine aldosterone was associated with low plasma renin and hypokalemia. RESULTS Mean followup was 44 months. Conversion to open surgery was necessary in 30 patients (14%) due to bleeding or adhesion and a procedure duration of greater than 3 hours. Mean operative time was 102 minutes (range 30 to 260). Six patients (2.8%) required blood transfusion. No deaths occurred. Postoperatively complications were observed in 10% of patients and the most frequent one was electrical myocardial ischemia without infarction. Mean postoperative pain medication was 17 mg. morphine sulfate equivalents (range 0 to 60). Mean and median hospital stay was 3.6 and 2.9 days, respectively (range 2 to 20). Postoperatively blood pressure was normal in 58% of patients without any drug, while treatment was decreased in the remainder. Kalemia was normalized in all cases. CONCLUSIONS Although some complications can occur, mostly at the beginning of the learning curve, laparoscopic transperitoneal adrenalectomy is effective treatment for primary hyperaldosteronism.


The Journal of Urology | 1995

RENIN SECRETING TUMORS: DIAGNOSIS, CONSERVATIVE SURGICAL APPROACH AND LONG-TERM RESULTS

F. Haab; Jean Marc Duclos; T. Guyenne; P.F. Plouin; P. Corvol

During the last 15 years 8 patients were diagnosed with renin secreting juxtaglomerular cell tumors among 30,000 hypertensive patients. Clinical characteristics included severe hypertension poorly medically controlled in young patients (mean age 22.3 years) and severe hypokalemia (mean 2.83 mmol./l.). Secondary hyperaldosteronism was present in all cases with a constant elevation of renin activity. Renal vein sampling was only positive in 64% of cases. Selective renal arteriography demonstrated an avascular area in 43% of the patients. Computerized tomography showed the tumor in all cases. Mean tumor size was 24 mm. (range 10 to 50). Conservative surgery was feasible in all patients. Perioperative ultrasonography was used for 3 intraparenchymal tumors. Hypertension and hypokalemia resolved within 1 week after surgery. At a mean followup of 98 months (range 24 to 204) no tumor recurrence was documented.


Urologia Internationalis | 2005

Management of pelvic stones larger than 20 mm: laparoscopic transperitoneal pyelolithotomy or percutaneous nephrolithotomy?

Paul Meria; Stéphane Milcent; François Desgrandchamps; Pierre Mongiat-Artus; Jean Marc Duclos; Pierre Teillac

Large pelvic stones are frequently managed with percutaneous nephrolithotomy (PCNL) but laparoscopic transperitoneal pyelolithotomy (LTP) can be an alternative. We compared PCNL and LTP for the treatment of pelvic stones >20 mm in diameter. Patients and Methods: Between November 1999 and November 2004, 16 consecutive patients, mean age 42, with a single pelvic stone >20 × 10 mm (group I), underwent LTP as first-line treatment or after shockwave lithotripsy failure. They were compared with a similar population of 16 consecutive patients, mean age 45 (group II), who underwent PCNL for the same indication and were assessed retrospectively. We evaluated operative characteristics, complications, and results for each technique. Results: There was no difference between the two groups regarding the characteristics of patients and stones. Operative time duration was significantly longer in group I (129 vs. 75 min; p = 0.001) and conversion was required in 2 patients (12%). The main postoperative complications were urinary leakage (2 patients, 12%) in group I and bleeding (3 patients, 18%) in group II, but only 1 required blood transfusion. Mean hospital stay was respectively 6.5 and 5.6 days in groups I and II (p = 0.17). Stone-free rates were assessed at 3 months and were not different between group I and group II (88 vs. 82%). Conclusions: The operative time of LTP is longer and the results of both techniques are comparable but postoperative morbidity is different. Specific indications of each technique must be determined although PCNL remains the gold standard for most large pelvic stones.


Revue de Médecine Interne | 2000

Progrès récents dans le diagnostic, l'évaluation pronostique et le traitement des phéochromocytomes

P.-F. Plouin; Anne-Paule Gimenez-Roqueplo; A La Batide Alanore; S Salenave; Jean Marc Duclos


Annales D Urologie | 2004

Adrenocortical secretory tumors

Pierre Mongiat-Artus; Miquel C; Paul Meria; A Hernigou; Jean Marc Duclos


Annales D Urologie | 2004

Tumeurs sécrétantes de la corticosurrénale

P Mongiat-Artus; Miquel C; Paul Meria; A Hernigou; Jean Marc Duclos


Annales D Urologie | 2004

Tumeurs non sécrétantes de la surrénale

E. Samaha; Paul Meria; A Hernigou; Jean Marc Duclos


Annales D Urologie | 2004

Tumeurs non scrtantes de la surrnale

E. Samaha; Paul Meria; A Hernigou; Jean Marc Duclos


Annales D Urologie | 2004

N?phrectomies difficiles

Jean Marc Duclos


Revue de Médecine Interne | 2000

Progrès récents dans le diagnostic, l’évaluation pronostique et le traitement des phéochromocytomes * 1 * De nombreuses études citées dans cet article ont été financées par l’Inserm et par le Programme hospitalier de recherches cliniques (AOM95201) dans le cadre du réseau COMETE (Cortico- et Médullo-surrénale, les Tumeurs Endocrines).

P.-F. Plouin; Anne-Paule Gimenez-Roqueplo; Agnès La Batide Alanore; Sylvie Salenave; Jean Marc Duclos

Collaboration


Dive into the Jean Marc Duclos's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Miquel C

Institut Gustave Roussy

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge